Kymera has $900 million in cash and no long-term debt, funding operations into mid-2027. Click here to read an analysis of ...

The drug’s mechanism of action simultaneously inhibits IL-4 and IL-13, which Sanofi says makes it a powerful treatment for type 2 inflammation in multiple diseases. Dupixent has already picked ...

Dupixent becomes the first-ever targeted therapy ... There is also the prospect of another therapy with a new mechanism of action in the next year or two after Amgen and AstraZeneca’s TSLP ...

Dupixent continues to be a significant growth ... targets a large market opportunity in thrombosis treatment. While the mechanism isn't fully de-risked and requires large, expensive Phase III ...

Dupixent has been a major success story for ... targeting anticoagulation with a differentiated mechanism of action. 2. Fianlimab: An antibody targeting LAG-3 for melanoma treatment, with ...